Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.
This description comes directly from the study's public registry record.
Christoph Roderburg, Professor · 04969589978719 · christoph.roderburg@med.uni-duesseldorf.de
Bianca Zaepf · 04969589978778 · zaepf.bianca@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| University Hospital of Düsseldorf | Düsseldorf, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07365930